Literature DB >> 16583132

Effect of different oral doses of isoniazid-rifampicin in rats.

Satya V Rana1, Ravinder Pal, Kim Vaiphie, Kartar Singh.   

Abstract

UNLABELLED: Hepatotoxicity is one of the most serious adverse effects of antituberculosis drugs. The aim of this study was to produce a rat model of isoniazid-rifampicin (INH-RIF) induced hepatotoxicity.
MATERIALS AND METHODS: Wistar rats (100-150 g) were treated with different doses of INH i.e. 25, 50 and 75 mg/kg/day with a fixed dose of RIF i.e. 50 mg/kg/day intragastrically for a period of 28 days. Serum glutamate oxaloacetate aminotransferase (SGOT), glutamate pyruvate aminotransferase (SGPT), bilirubin (Bil) and alkaline phosphatase (ALP) were estimated at 0,14, 21 and 28 days in rats. Histological analysis was carried out to assess the liver.
RESULTS: Treatment of rats with INH-RIF (50 mg/kg/day each) induced hepatotoxicity as judged by elevated serum SGPT, SGOT, Bil and ALP as compared with their base line. Histological evaluation of INH-RIF induced hepatotoxicity also showed liver damage.
CONCLUSION: The present study suggests that 50 mg/kg/day each of INH-RIF was selected as hepatotoxic dose (i.e. minimum dose with maximum hepatotoxicity) in wistar rats.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16583132     DOI: 10.1007/s11010-006-9145-3

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  14 in total

1.  Myocardial necrosis and severe metabolic acidosis associated with isoniazid poisoning in a dog.

Authors:  I Frank; D Lahav; I Aroch
Journal:  Vet Rec       Date:  2002-11-23       Impact factor: 2.695

2.  Efficacy of microencapsulated rifampin in Mycobacterium tuberculosis-infected mice.

Authors:  D C Quenelle; J K Staas; G A Winchester; E L Barrow; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Isoniazid- and rifampicin-induced oxidative hepatic injury--protection by N-acetylcysteine.

Authors:  S Attri; S V Rana; K Vaiphei; C P Sodhi; R Katyal; R C Goel; C K Nain; K Singh
Journal:  Hum Exp Toxicol       Date:  2000-09       Impact factor: 2.903

4.  The guinea pig as a model for isoniazid-induced reactions.

Authors:  G B Heisey; H C Hughes; C M Lang; H Rozmiarek
Journal:  Lab Anim Sci       Date:  1980-02

5.  Comparative hepatic toxicity: prechronic/chronic liver toxicity in rodents.

Authors:  Jerry F Hardisty; Amy E Brix
Journal:  Toxicol Pathol       Date:  2005       Impact factor: 1.902

6.  Protective effect of a 50% hydroalcoholic fruit extract of Emblica officinalis against anti-tuberculosis drugs induced liver toxicity.

Authors:  S A Tasduq; P Kaisar; D K Gupta; B K Kapahi; H S Maheshwari; S Jyotsna; R K Johri
Journal:  Phytother Res       Date:  2005-03       Impact factor: 5.878

7.  The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity.

Authors:  A Fernández-Villar; B Sopeña; J Fernández-Villar; R Vázquez-Gallardo; F Ulloa; V Leiro; M Mosteiro; L Piñeiro
Journal:  Int J Tuberc Lung Dis       Date:  2004-12       Impact factor: 2.373

8.  Dosimetric comparisons of particle deposition and retention in rats and humans.

Authors:  James S Brown; William E Wilson; Lester D Grant
Journal:  Inhal Toxicol       Date:  2005 Jun-Jul       Impact factor: 2.724

Review 9.  Antituberculosis drug-induced hepatitis: risk factors, prevention and management.

Authors:  Z Hussain; P Kar; S A Husain
Journal:  Indian J Exp Biol       Date:  2003-11       Impact factor: 0.818

Review 10.  Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis.

Authors:  J R Mitchell; H J Zimmerman; K G Ishak; U P Thorgeirsson; J A Timbrell; W R Snodgrass; S D Nelson
Journal:  Ann Intern Med       Date:  1976-02       Impact factor: 25.391

View more
  6 in total

1.  The Janeway gastrostomy tube for recurrent gastric intubations: a novel and simple animal model.

Authors:  Ali Ugur Emre; Guldeniz C Karadeniz; Oge Tascilar; Bulent H Ucan; Oktay Irkorucu; Kemal Karakaya; Mustafa Comert
Journal:  Dig Dis Sci       Date:  2007-10-12       Impact factor: 3.199

2.  Association of Antituberculosis Treatment and Lower Risk of Hyperlipidemia in Taiwanese Patients: A Population-Based Case-Control Study.

Authors:  Ying-Ray Lee; N I Tien; Cheng-Li Lin; Hsin-Yi Shen; DA-Tian Bau; Yun-Ping Lim
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

3.  Lack of liver injury in Wistar rats treated with the combination of isoniazid and rifampicin.

Authors:  Imir G Metushi; Jack Uetrecht
Journal:  Mol Cell Biochem       Date:  2013-10-23       Impact factor: 3.396

4.  Amelioration of Nephrotoxicity in Mice Induced by Antituberculosis Drugs Using Ensete ventricosum (Welw.) Cheesman Corm Extract.

Authors:  Abebe Dukessa Dubiwak; Urge Gerema; Daba Abdisa; Ebsa Tofik; Wondu Reta
Journal:  Int J Nephrol       Date:  2022-03-17

5.  Hepatoprotective Activity of Heptoplus on Isoniazid and Rifampicin Induced Liver Damage in Rats.

Authors:  M Sankar; Johanna Rajkumar; Dorai Sridhar
Journal:  Indian J Pharm Sci       Date:  2015 Sep-Oct       Impact factor: 0.975

6.  Hepatoprotective agent tethered isoniazid for the treatment of drug-induced hepatotoxicity: Synthesis, biochemical and histopathological evaluation.

Authors:  Charan Singh; Laxmikant Jodave; Tara Datt Bhatt; Manjinder Singh Gill; Sarasija Suresh
Journal:  Toxicol Rep       Date:  2014-10-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.